{"component": "definition", "props": {"groups": [{"samples": [{"hash": "8fITM2u9t5Q", "uri": "https://data.gov.uk/data/contracts-finder-archive/download/1619257/3d78fd52-e2e4-4059-ac81-96eb3ec6b920", "label": "Note", "score": 9.421628952, "published": false}, {"hash": "it0ZrTicqbA", "uri": "https://data.gov.uk/data/contracts-finder-archive/download/1617353/a97bc40f-4687-441e-8d65-c881c5676c11", "label": "Note", "score": 9.4202604294, "published": false}, {"hash": "6AWqAQhKkQQ", "uri": "https://data.gov.uk/data/contracts-finder-archive/download/1565829/4d97e43a-32b2-4823-aacc-98838bd9ac70", "label": "Note", "score": 9.3668718338, "published": false}], "size": 47, "snippet": "means that in the reasonable opinion of the Customer, Deliverables completed by the Supplier are fit for purpose, completed on time and otherwise meet all the criteria defined under this Contract;", "snippet_links": [{"key": "of-the-customer", "type": "clause", "offset": [37, 52]}, {"key": "completed-by", "type": "clause", "offset": [67, 79]}, {"key": "the-supplier", "type": "definition", "offset": [80, 92]}, {"key": "fit-for-purpose", "type": "definition", "offset": [97, 112]}, {"key": "on-time", "type": "definition", "offset": [124, 131]}, {"key": "the-criteria", "type": "clause", "offset": [155, 167]}, {"key": "under-this-contract", "type": "clause", "offset": [176, 195]}], "hash": "b1fd39af01f8d5987d88b84315d609b9", "id": 1}, {"samples": [{"hash": "aOWMAdboopN", "uri": "https://regulations.delaware.gov/register/july2020/proposed/24%20DE%20Reg%2014%2007-01-20.pdf", "label": "regulations.delaware.gov", "score": 10.248459816, "published": false}, {"hash": "hvTushtXQUs", "uri": "http://regulations.delaware.gov/AdminCode/title9/Division%20of%20Family%20Services%20Office%20of%20Child%20Care%20Licensing/100/101.pdf", "label": "regulations.delaware.gov", "score": 7.8542094231, "published": false}, {"hash": "4PwLhPNmPjw", "uri": "https://regulations.delaware.gov/register/september2021/emergency/25%20DE%20Reg%20235%2009-01-21.pdf", "label": "regulations.delaware.gov", "score": 5.0, "published": false}], "size": 28, "snippet": "means earning at least a grade of C- or its equivalent in early childhood education or child development course work from a regionally accredited college or university or completion of a quality- assured training course.", "snippet_links": [{"key": "a-grade", "type": "clause", "offset": [23, 30]}, {"key": "early-childhood-education", "type": "definition", "offset": [58, 83]}, {"key": "child-development-course-work", "type": "definition", "offset": [87, 116]}, {"key": "regionally-accredited-college-or-university", "type": "definition", "offset": [124, 167]}, {"key": "completion-of-a", "type": "clause", "offset": [171, 186]}, {"key": "training-course", "type": "clause", "offset": [204, 219]}], "hash": "1e716e2c01af325442fd45b2d6ed1230", "id": 2}, {"samples": [{"hash": "1Zvno90WuwO", "uri": "https://www.oregon.gov/obmt/Documents/Effective%2007.01.2025%20OAR-WC.pdf", "label": "www.oregon.gov", "score": 20.4921321869, "published": false}, {"hash": "hdg9Cu7IQSO", "uri": "https://www.oregon.gov/obmt/Documents/Effective%2007.01.2024%20OAR.WC.pdf", "label": "www.oregon.gov", "score": 19.2095718384, "published": false}, {"hash": "8IPWpW1rDRz", "uri": "https://www.oregon.gov/obmt/Documents/Effective%2007.01.2023%20OAR.WC.pdf", "label": "www.oregon.gov", "score": 11.7611227036, "published": false}], "size": 17, "snippet": "means the written receipt of credit from classes taken at a community college or university or the written receipt of a certificate from a program or private career school.", "snippet_links": [{"key": "receipt-of-credit", "type": "clause", "offset": [18, 35]}, {"key": "community-college-or-university", "type": "clause", "offset": [60, 91]}, {"key": "receipt-of-a", "type": "clause", "offset": [107, 119]}, {"key": "private-career-school", "type": "definition", "offset": [150, 171]}], "hash": "e94ae0c0d33abed128bb89eca567463a", "id": 3}, {"samples": [{"hash": "9gu6ldaq1oD", "uri": "/contracts/9gu6ldaq1oD#successful-completion", "label": "License Agreement (GT Biopharma, Inc.)", "score": 28.6084880829, "published": true}, {"hash": "cggAZf4JHk2", "uri": "/contracts/cggAZf4JHk2#successful-completion", "label": "License Agreement (Oxis International Inc)", "score": 27.8309383392, "published": true}, {"hash": "4fgxKBUcTOJ", "uri": "/contracts/4fgxKBUcTOJ#successful-completion", "label": "License Agreement (Oxis International Inc)", "score": 27.754278183, "published": true}], "size": 16, "snippet": "means with respect to a specified human clinical trial the achievement as determined by the sponsor of such trial of the primary clinical endpoint identified in the protocol for such trial.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [6, 21]}, {"key": "human-clinical-trial", "type": "definition", "offset": [34, 54]}, {"key": "the-sponsor", "type": "clause", "offset": [88, 99]}, {"key": "the-primary", "type": "clause", "offset": [117, 128]}, {"key": "the-protocol", "type": "clause", "offset": [161, 173]}], "hash": "01ff5c83d35a24f87bf7131acb04c0f6", "id": 4}, {"samples": [{"hash": "h0w24CPQv7G", "uri": "https://post.colorado.gov/sites/post/files/documents/Post-Manual-2007.pdf", "label": "post.colorado.gov", "score": 6.7330594063, "published": false}, {"hash": "9ArTwJBLkB3", "uri": "https://www.colorado.gov/pacific/sites/default/files/atoms/files/Post-Manual-2005.pdf", "label": "www.colorado.gov", "score": 6.5961670876, "published": false}, {"hash": "lv835Y0xnNS", "uri": "https://www.colorado.gov/pacific/sites/default/files/atoms/files/Post-Manual-2004.pdf", "label": "www.colorado.gov", "score": 6.4661192894, "published": false}], "size": 14, "snippet": "means a score of seventy (70) percent or greater, or a grade of \u201cC\u201d or better, or a rating of pass, if offered as pass/fail.", "snippet_links": [{"key": "a-grade", "type": "clause", "offset": [53, 60]}], "hash": "726368b5cf59b1aca365542666decc2e", "id": 5}, {"samples": [{"hash": "1H6q0C8Yk2i", "uri": "/contracts/1H6q0C8Yk2i#successful-completion", "label": "Sponsored Research Agreement (Med BioGene Inc.)", "score": 21.3997268677, "published": true}, {"hash": "hNtyUDThkEK", "uri": "/contracts/hNtyUDThkEK#successful-completion", "label": "Sponsored Research Agreement (Med BioGene Inc.)", "score": 21.2108154297, "published": true}], "size": 12, "snippet": "In this Agreement, \u201cSuccessful Completion\u201d means material completion by UHN of their work under each relevant Phase of the Research Program within the relevant time period prescribed in Schedule A; provided that, in respect of each Phase of the Research Program, in the event that there is:", "snippet_links": [{"key": "in-this-agreement", "type": "clause", "offset": [0, 17]}, {"key": "material-completion", "type": "clause", "offset": [49, 68]}, {"key": "phase-of", "type": "clause", "offset": [110, 118]}, {"key": "the-research-program", "type": "clause", "offset": [119, 139]}, {"key": "relevant-time-period", "type": "definition", "offset": [151, 171]}, {"key": "schedule-a", "type": "clause", "offset": [186, 196]}, {"key": "provided-that", "type": "clause", "offset": [198, 211]}, {"key": "in-respect-of", "type": "clause", "offset": [213, 226]}, {"key": "in-the-event", "type": "clause", "offset": [263, 275]}], "hash": "71b95312080eaae89062b3a88af6dc60", "id": 6}, {"samples": [{"hash": "5ON9FYeq2SB", "uri": "https://post.colorado.gov/sites/post/files/documents/November%202023_Manual_RULES%20(1).pdf", "label": "post.colorado.gov", "score": 15.551656723, "published": false}, {"hash": "4xYe4bTIqhl", "uri": "https://post.colorado.gov/sites/post/files/documents/1%20-%20Manual_RULES.pdf", "label": "Code of Ethics", "score": 15.4093084335, "published": false}, {"hash": "3kZ3LmErlvD", "uri": "https://post.colorado.gov/sites/post/files/documents/Rule%201_0.pdf", "label": "post.colorado.gov", "score": 9.9226560593, "published": false}], "size": 9, "snippet": "means a score of seventy (70) percent or greater, or a grade of \"C\" or better, or a rating of pass, if offered as pass/fail, in a POST approved academy or program. For the certification examination passing score, see Rule 15.", "snippet_links": [{"key": "a-grade", "type": "clause", "offset": [53, 60]}, {"key": "approved-academy", "type": "definition", "offset": [135, 151]}, {"key": "certification-examination", "type": "definition", "offset": [172, 197]}, {"key": "passing-score", "type": "clause", "offset": [198, 211]}, {"key": "rule-15", "type": "clause", "offset": [217, 224]}], "hash": "03b8de6e0e82e5be581bf3650ba75abd", "id": 7}, {"samples": [{"hash": "kd4nsXNMpRD", "uri": "/contracts/kd4nsXNMpRD#successful-completion", "label": "Amendment Agreement", "score": 31.3408622742, "published": true}, {"hash": "i0ArzaVRc8u", "uri": "/contracts/i0ArzaVRc8u#successful-completion", "label": "Amendment Agreement (Iaso Pharma Inc)", "score": 22.4757022858, "published": true}, {"hash": "eKYUWIXe4yl", "uri": "/contracts/eKYUWIXe4yl#successful-completion", "label": "Amendment Agreement (Iaso Pharma Inc)", "score": 22.4757022858, "published": true}], "size": 9, "snippet": "means that the Phase III Clinical Trial (a) achieved its primary clinical endpoint as defined in the protocol for the Phase III Clinical Trial and (b) had a side effect profile that does not adversely affect the Product\u2019s eligibility to be subject to an NDA; and", "snippet_links": [{"key": "phase-iii-clinical-trial", "type": "definition", "offset": [15, 39]}, {"key": "the-protocol", "type": "clause", "offset": [97, 109]}, {"key": "side-effect", "type": "definition", "offset": [157, 168]}, {"key": "adversely-affect", "type": "definition", "offset": [191, 207]}, {"key": "the-product", "type": "clause", "offset": [208, 219]}, {"key": "subject-to", "type": "clause", "offset": [240, 250]}], "hash": "7a8b0b287e380cf34cafec18ec112202", "id": 8}, {"samples": [{"hash": "jhpsXmEOGt8", "uri": "https://democratic.lincoln.gov.uk/documents/s71765/Executive%20July%202024%20Acquisition%20Policy%20DRAFT_.pdf", "label": "democratic.lincoln.gov.uk", "score": 19.4706306458, "published": false}, {"hash": "3htTnEWvf66", "uri": "https://democratic.lincoln.gov.uk/documents/b20306/Housing%20Scrutiny%20Sub%20Committee%20-%2011%20March%202024-%20Reports%20To%20Follow%2011th-Mar-2024%2018.00%20Housing%20Sc.pdf?T=9", "label": "democratic.lincoln.gov.uk", "score": 19.1553344727, "published": false}, {"hash": "fZrxqODIDE1", "uri": "https://democratic.lincoln.gov.uk/documents/s69724/HSSC%20Jan%202024%20Acquisition%20Policy_%20002.pdf", "label": "democratic.lincoln.gov.uk", "score": 19.1428146362, "published": false}], "size": 8, "snippet": "means Completion of the Refurbishment Programme within the Agreed Timescales", "snippet_links": [{"key": "completion-of-the", "type": "clause", "offset": [6, 23]}], "hash": "558b97372987156a9cb2b97aede6a62b", "id": 9}, {"samples": [{"hash": "aqqfj3FR3dp", "uri": "/contracts/aqqfj3FR3dp#successful-completion", "label": "License and Commercialization Agreement (Bellerophon Therapeutics, Inc.)", "score": 26.2429847717, "published": true}, {"hash": "eqgtMpj78Xc", "uri": "/contracts/eqgtMpj78Xc#successful-completion", "label": "License and Commercialization Agreement (Bellerophon Therapeutics LLC)", "score": 26.032169342, "published": true}, {"hash": "117iSGFYTmU", "uri": "/contracts/117iSGFYTmU#successful-completion", "label": "License and Commercialization Agreement (Bellerophon Therapeutics LLC)", "score": 25.3641338348, "published": true}], "size": 8, "snippet": "means:\n(a) with respect to the On-Going Phase I/II Trial, no treatment-related safety findings during the treatment period and the six (6) month follow up period, that were considered by the Independent Safety Monitoring Board for the On-Going Phase I/II Trial (in accordance with and subject to the Independent Safety Monitoring Board Charter attached hereto as Schedule 1.42(a)) to be of sufficient concern to discontinue the On-Going Phase I/II Trial;\n(b) with respect to the Interim Analysis of the Pivotal Clinical Trial/Phase IIb Proof of Concept, safety and efficacy data from completion of all patients at the [**] follow up demonstrates more than a [**] probability of meeting pre-specified endpoints at [**] in the Pivotal Clinical Trial, and no apparent safety signal in the treatment group for the entire cohort at all times;\n(c) with respect to the Pivotal Clinical Trial for the Primary Indication, safety and efficacy data from completion of all patients at the [**] follow up meets the primary endpoint and demonstrates a positive benefit-to-risk ratio to enable FDA submission; and\n(d) with respect to all other clinical trials of a Product, that the JDC has determined that the final results of such clinical trial have achieved the success criteria established by the JDC with respect to such clinical trial.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [11, 26]}, {"key": "treatment-period", "type": "clause", "offset": [106, 122]}, {"key": "the-independent", "type": "clause", "offset": [187, 202]}, {"key": "monitoring-board", "type": "definition", "offset": [210, 226]}, {"key": "in-accordance-with", "type": "clause", "offset": [262, 280]}, {"key": "subject-to-the", "type": "definition", "offset": [285, 299]}, {"key": "board-charter", "type": "definition", "offset": [330, 343]}, {"key": "interim-analysis", "type": "definition", "offset": [479, 495]}, {"key": "pivotal-clinical-trial", "type": "definition", "offset": [503, 525]}, {"key": "phase-iib", "type": "definition", "offset": [526, 535]}, {"key": "proof-of-concept", "type": "clause", "offset": [536, 552]}, {"key": "safety-and-efficacy", "type": "clause", "offset": [554, 573]}, {"key": "completion-of", "type": "definition", "offset": [584, 597]}, {"key": "all-patients", "type": "definition", "offset": [598, 610]}, {"key": "safety-signal", "type": "definition", "offset": [765, 778]}, {"key": "treatment-group", "type": "definition", "offset": [786, 801]}, {"key": "at-all-times", "type": "definition", "offset": [824, 836]}, {"key": "primary-indication", "type": "definition", "offset": [893, 911]}, {"key": "primary-endpoint", "type": "definition", "offset": [1002, 1018]}, {"key": "risk-ratio", "type": "definition", "offset": [1058, 1068]}, {"key": "fda-submission", "type": "clause", "offset": [1079, 1093]}, {"key": "other-clinical-trials", "type": "clause", "offset": [1123, 1144]}, {"key": "the-jdc", "type": "clause", "offset": [1164, 1171]}, {"key": "final-results", "type": "definition", "offset": [1196, 1209]}, {"key": "success-criteria", "type": "definition", "offset": [1251, 1267]}], "hash": "f06be00f0346bc4bb563fa02b12b2813", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIec3VjY2Vzc2Z1bC1jb21wbGV0aW9uIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Successful Completion", "size": 511, "snippet": "means that in the reasonable opinion of the Customer, Deliverables completed by the Supplier are fit for purpose, completed on time and otherwise meet all the criteria defined under this Contract;", "id": "successful-completion", "examples": ["The business review meeting may include, but is not limited to, the following: \u2022 <strong>Successful completion</strong> of deliverables \u2022 Review of the Contractor\u2019s performance \u2022 Review of minimum required reports \u2022 Addressing of any elevated Customer issues \u2022 Review of continuous improvement ideas that may help lower total costs and improve business efficiencies.", "<strong>Successful completion</strong> of a driving test and defensive driving school or Fire Service Vehicle Operator (FSVO).", "<strong>Successful completion</strong> of the probationary period is required to qualify for the supplemental compensation from the County.", "<strong>Successful completion</strong> and State certification on both the written and practical tests on the Fire Apparatus Engineer test.", "<strong>Successful completion</strong> of Firefighter probationary period, to include FF II or Basic Operations Firefighter, EMT certification, a valid appropriate class driver\u2019s license, and a minimum of one (1) year of service.", "<strong>Successful completion</strong> of said initial medical and physical standards shall become a component of the selection process for the initial appointment of persons to positions covered by this Agreement.", "<strong>Successful completion</strong> of Deconversion Services is subject to the cooperation of Customer, the vendor of the system or service to which Licensee intends to migrate, and specific written, specific definition of the data fields and formats and to be extracted.", "<strong>Successful completion</strong> of the probationary period must occur within twelve (12) months or the employee shall be terminated.", "<strong>Successful completion</strong> of EMSP 1501 and EMSP 1164, at a minimum, is required for students to receive the TXDSHS/NREMT mandated course completion certificate.", "<strong>Successful completion</strong> of the probationary period is required in order to qualify for the supplemental compensation from the District."], "related": [["final-completion", "Final Completion", "Final Completion"], ["successful-vendor", "Successful Vendor", "Successful Vendor"], ["final-completion-date", "Final Completion Date", "Final Completion Date"], ["completion", "Completion", "Completion"], ["completion-period", "Completion Period", "Completion Period"]], "related_snippets": [], "updated": "2025-11-18T05:27:50+00:00"}, "json": true, "cursor": ""}}